<DOC>
	<DOCNO>NCT01409408</DOCNO>
	<brief_summary>Assess aliskiren capable enhance vascular stiffness endothelial function compare theses effect renin activity concentration obtain calcium channel blocker , amlodipine , patient diabetes mellitus type 2 blood pressure control 100 mg per day losartan .</brief_summary>
	<brief_title>Comparison Amlodipine Aliskiren Diabetic Hypertensive Patient With Blood Pressure Not Controlled Losartan</brief_title>
	<detailed_description>Hypertension diabetes mellitus important risk factor cardiovascular morbidity mortality . Endothelial dysfunction vascular rigidity two pathophysiological mechanism may explain relationship . Recent publication show ACEi ( angiotensin convert enzyme inhibitor ) ARB ( angiotensin receptor blocker ) capable improve vascular stiffness endothelial function , effect occur despite blood pressure reduction . The major debate persists drug associate ACEi ARB achieve blood pressure control diabetic patient . Recent study show even patient ACEi ARB therapy may residual activity renin-angiotensin-aldosterone system ( RASS ) . Direct renin inhibitor ( DRI ) new class anti-hypertensive drug may complement blockade RASS . Aliskiren first drug class complete phase 3 study market 21th century . It 's main advantage DRI may reduce angiotensin II aldosterone synthesis without increase renin level . This study main objective ass aliskiren capable enhance vascular stiffness endothelial function compare theses effect obtain calcium channel blocker , amlodipine , patient diabetes mellitus type 2 blood pressure control 100 mg per day losartan . Vascular stiffness endothelial function measure : pulse wave velocity , augmentation index , brachial artery flow-mediated vasodilation , peripheral arterial tonometry ( EndoPat ) . Another main objective compare plasma renin activity concentration group .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Ambulatorial patient age 40 70 yearsold . Systemic arterial hypertension previously diagnose use two less antihypertensive drug precede 4 week . Those patient without antihypertensive drug prescribe last 4 week office systolic blood pressure 140 159 mmHg diastolic 90 109 mmHg . Type 2 diabetes mellitus use oral medication change precede 4 week . Glycated hemoglobin A1c le 9.0 % . Accepted consent form . Office systolic blood pressure equal 180 mmHg , without treatment Office diastolic blood pressure equal 110 mmHg , without treatment Evidences secondary cause hypertension Glycated hemoglobin A1c &gt; 9.0 % Insulin therapy Chronic kidney disease level 3 5 dialysis Advanced target organ lesion , obtain history additional exam , define : previous myocardial infarction , heart failure ejection fraction le 40 % , cerebral vascular accident ( ischemic hemorrhagic ) , peripheral vascular disease ( claudication doppler obstruction &gt; 50 % vascular lumen ) , retinopathy visual loss , symptomatic neuropathy . Cardiac arrhythmia , except ectopic beat Any clinical disabling condition , opinion investigator , may confound prejudice study result .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Vascular stiffness</keyword>
	<keyword>Endothelial function</keyword>
</DOC>